![HeavenAdmιn](/data/avatars/l/6/6850.jpg?1607099380)
HeavenAdmιn
Reaching Perfection
- Joined
- May 8, 2020
- Posts
- 1,191
- Reputation
- 4,619
"The FDA recently approved clascoterone cream 1% for the treatment of acne in patients aged 12 years or older.1 This is the first FDA-approved treatment in 40 years to target a new mechanism of action for acne."
"Clascoterone cream 1% is an androgen receptor inhibitor that is thought to compete with androgens, specifically dihydrotestosterone, for binding to the androgen receptors in sebaceous glands and hair follicles. Two phase 3 clinical trials showed clascoterone cream 1% achieved treatment success, reduced acne lesions, and had a favorable safety profile compared with vehicle."
But here comes the juicy part:
"Clascoterone cream 1% targets androgen receptors at the site of application. This inhibits the local (skin) effects of dihydrotestosterone (DHT). Apparently, DHT is a key driver of acne lesion development. Most people wrongly assume it is solely testosterone."
"If approved, clascoterone cream 1% will represent the first new mechanism of action in the treatment of acne in almost 40 years. Interestingly, if Breezula is approved for hair loss in 2021, it will be the first new topical or oral treatment for hair loss in almost 25 years."
Basically this hair loss product called Breezula, which is expected to come to the market in 2023, has the key ingredient clascoterone cream 1%.
Results from trials conducted of Breezula.
"Clascoterone cream 1% is an androgen receptor inhibitor that is thought to compete with androgens, specifically dihydrotestosterone, for binding to the androgen receptors in sebaceous glands and hair follicles. Two phase 3 clinical trials showed clascoterone cream 1% achieved treatment success, reduced acne lesions, and had a favorable safety profile compared with vehicle."
But here comes the juicy part:
"Clascoterone cream 1% targets androgen receptors at the site of application. This inhibits the local (skin) effects of dihydrotestosterone (DHT). Apparently, DHT is a key driver of acne lesion development. Most people wrongly assume it is solely testosterone."
"If approved, clascoterone cream 1% will represent the first new mechanism of action in the treatment of acne in almost 40 years. Interestingly, if Breezula is approved for hair loss in 2021, it will be the first new topical or oral treatment for hair loss in almost 25 years."
Basically this hair loss product called Breezula, which is expected to come to the market in 2023, has the key ingredient clascoterone cream 1%.
Results from trials conducted of Breezula.